TWI257302B - Controlled-release of an active substance into a high fat environment - Google Patents

Controlled-release of an active substance into a high fat environment Download PDF

Info

Publication number
TWI257302B
TWI257302B TW092134835A TW92134835A TWI257302B TW I257302 B TWI257302 B TW I257302B TW 092134835 A TW092134835 A TW 092134835A TW 92134835 A TW92134835 A TW 92134835A TW I257302 B TWI257302 B TW I257302B
Authority
TW
Taiwan
Prior art keywords
composition
environment
core
weight
drug
Prior art date
Application number
TW092134835A
Other languages
English (en)
Chinese (zh)
Other versions
TW200425888A (en
Inventor
Mark Brian Chidlaw
Dwayne Thomas Friesen
Scott Max Herbig
James Alan Schrive Nightingale
Cynthia Ann Oksanen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TW200425888A publication Critical patent/TW200425888A/zh
Application granted granted Critical
Publication of TWI257302B publication Critical patent/TWI257302B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW092134835A 2002-12-11 2003-12-10 Controlled-release of an active substance into a high fat environment TWI257302B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43286002P 2002-12-11 2002-12-11

Publications (2)

Publication Number Publication Date
TW200425888A TW200425888A (en) 2004-12-01
TWI257302B true TWI257302B (en) 2006-07-01

Family

ID=32508002

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092134835A TWI257302B (en) 2002-12-11 2003-12-10 Controlled-release of an active substance into a high fat environment

Country Status (18)

Country Link
US (1) US20040121015A1 (enExample)
EP (1) EP1572163A1 (enExample)
JP (1) JP2006510655A (enExample)
KR (1) KR20050088311A (enExample)
CN (1) CN1726012A (enExample)
AR (1) AR042340A1 (enExample)
AU (1) AU2003283688A1 (enExample)
BR (1) BR0317275A (enExample)
CA (1) CA2508722A1 (enExample)
CO (1) CO5570656A2 (enExample)
MX (1) MXPA05005812A (enExample)
NO (1) NO20053068L (enExample)
NZ (1) NZ539915A (enExample)
PL (1) PL377479A1 (enExample)
RU (1) RU2308263C2 (enExample)
TW (1) TWI257302B (enExample)
WO (1) WO2004052343A1 (enExample)
ZA (1) ZA200503812B (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
ES2314227T7 (es) * 2002-04-09 2012-11-19 Flamel Technologies Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
CA2589537A1 (en) * 2004-12-02 2006-06-08 Stephen Craig Dyar Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
EP1845947B1 (en) * 2005-01-28 2008-12-31 Pfizer Products Inc. Fast-disintegrating microporous binder and process for making it
US8431156B2 (en) * 2005-02-22 2013-04-30 Sun Pharma Advanced Research Company Ltd. Pharmaceutical composition
EP1874282B1 (en) * 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US8730031B2 (en) 2005-04-28 2014-05-20 Proteus Digital Health, Inc. Communication system using an implantable device
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
CA2789262C (en) 2005-04-28 2016-10-04 Proteus Digital Health, Inc. Pharma-informatics system
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
US8547248B2 (en) 2005-09-01 2013-10-01 Proteus Digital Health, Inc. Implantable zero-wire communications system
CA2650920C (en) 2006-05-02 2016-10-18 Proteus Biomedical, Inc. Patient customized therapeutic regimens
US8054140B2 (en) 2006-10-17 2011-11-08 Proteus Biomedical, Inc. Low voltage oscillator for medical devices
JP5916277B2 (ja) 2006-10-25 2016-05-11 プロテウス デジタル ヘルス， インコーポレイテッド 摂取可能な制御活性化識別子
EP2069004A4 (en) 2006-11-20 2014-07-09 Proteus Digital Health Inc PERSONAL HEALTH SIGNAL RECEIVERS WITH ACTIVE SIGNAL PROCESSING
CN101686800A (zh) 2007-02-01 2010-03-31 普罗秋斯生物医学公司 可摄入事件标记器系统
JP5614991B2 (ja) * 2007-02-14 2014-10-29 プロテウス デジタル ヘルス， インコーポレイテッド 大表面積電極を有する体内型電源
US8932221B2 (en) 2007-03-09 2015-01-13 Proteus Digital Health, Inc. In-body device having a multi-directional transmitter
WO2008112578A1 (en) 2007-03-09 2008-09-18 Proteus Biomedical, Inc. In-body device having a deployable antenna
US20080299188A1 (en) * 2007-05-14 2008-12-04 Pfizer Inc. Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug
US8540632B2 (en) 2007-05-24 2013-09-24 Proteus Digital Health, Inc. Low profile antenna for in body device
EP2192946B1 (en) 2007-09-25 2022-09-14 Otsuka Pharmaceutical Co., Ltd. In-body device with virtual dipole signal amplification
US20090105561A1 (en) * 2007-10-17 2009-04-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8707964B2 (en) * 2007-10-31 2014-04-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8789536B2 (en) 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808276B2 (en) * 2007-10-23 2014-08-19 The Invention Science Fund I, Llc Adaptive dispensation in a digestive tract
US8808271B2 (en) * 2007-10-31 2014-08-19 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090163894A1 (en) * 2007-10-31 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
KR100920106B1 (ko) * 2007-11-14 2009-10-01 경북대학교 산학협력단 구연산 실데나필을 경피적으로 전달하기 위한 조절 약물전달체 및 이를 포함하는 경피 패치
AU2008329620B2 (en) 2007-11-27 2014-05-08 Otsuka Pharmaceutical Co., Ltd. Transbody communication systems employing communication channels
EP3235491B1 (en) 2008-03-05 2020-11-04 Proteus Digital Health, Inc. Multi-mode communication ingestible event markers and systems
WO2010005877A2 (en) 2008-07-08 2010-01-14 Proteus Biomedical, Inc. Ingestible event marker data framework
CA2734251A1 (en) 2008-08-13 2010-02-18 Proteus Biomedical, Inc. Ingestible circuitry
EP2328601B1 (en) 2008-08-15 2020-01-22 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
CA2743781C (en) * 2008-11-13 2013-10-01 Proteus Biomedical, Inc. Ingestible therapy activator system and method
CN102271578B (zh) * 2008-12-11 2013-12-04 普罗秋斯数字健康公司 使用便携式电子内脏造影系统的胃肠功能的评估及其使用方法
TWI503101B (zh) 2008-12-15 2015-10-11 Proteus Digital Health Inc 與身體有關的接收器及其方法
US9439566B2 (en) 2008-12-15 2016-09-13 Proteus Digital Health, Inc. Re-wearable wireless device
US9659423B2 (en) 2008-12-15 2017-05-23 Proteus Digital Health, Inc. Personal authentication apparatus system and method
SG172847A1 (en) 2009-01-06 2011-08-29 Proteus Biomedical Inc Pharmaceutical dosages delivery system
AU2010203625A1 (en) 2009-01-06 2011-07-21 Proteus Digital Health, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
GB2480965B (en) 2009-03-25 2014-10-08 Proteus Digital Health Inc Probablistic pharmacokinetic and pharmacodynamic modeling
MY161146A (en) 2009-04-28 2017-04-14 Proteus Digital Health Inc Highly-reliable ingestible event markers and methods for using the same
US9149423B2 (en) 2009-05-12 2015-10-06 Proteus Digital Health, Inc. Ingestible event markers comprising an ingestible component
MX2012001660A (es) 2009-08-06 2012-03-26 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para adminstracion oral.
EP2467707A4 (en) 2009-08-21 2014-12-17 Proteus Digital Health Inc DEVICE AND METHOD FOR MEASURING BIOLOGICAL PARAMETERS
TWI517050B (zh) 2009-11-04 2016-01-11 普羅托斯數位健康公司 供應鏈管理之系統
UA109424C2 (uk) 2009-12-02 2015-08-25 Фармацевтичний продукт, фармацевтична таблетка з електронним маркером і спосіб виготовлення фармацевтичної таблетки
SG182825A1 (en) 2010-02-01 2012-09-27 Proteus Biomedical Inc Data gathering system
KR101193495B1 (ko) * 2010-02-01 2012-10-23 한미사이언스 주식회사 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물
CA2790213A1 (en) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
SG10201502720VA (en) 2010-04-07 2015-05-28 Proteus Digital Health Inc Miniature ingestible device
TWI557672B (zh) 2010-05-19 2016-11-11 波提亞斯數位康健公司 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
ES2919136T3 (es) 2010-08-11 2022-07-22 Ironwood Pharmaceuticals Inc Formulaciones estables de linaclotida
JP2014504902A (ja) 2010-11-22 2014-02-27 プロテウス デジタル ヘルス， インコーポレイテッド 医薬品を有する摂取可能なデバイス
JP2014514032A (ja) 2011-03-11 2014-06-19 プロテウス デジタル ヘルス， インコーポレイテッド 様々な物理的構成を備えた着用式個人身体関連装置
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
KR101898964B1 (ko) 2011-07-21 2018-09-14 프로테우스 디지털 헬스, 인코포레이티드 모바일 통신 장치, 시스템, 및 방법
PL2776055T3 (pl) 2011-08-17 2017-06-30 Ironwood Pharmaceuticals, Inc. Sposoby leczenia zaburzeń żołądkowo-jelitowych
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
KR20150038038A (ko) 2012-07-23 2015-04-08 프로테우스 디지털 헬스, 인코포레이티드 섭취 가능한 부품을 포함하는 섭취 가능한 이벤트 마커를 제조하기 위한 기술
HK1210893A1 (en) 2012-10-18 2016-05-06 Otsuka Pharmaceutical Co., Ltd. Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
US11149123B2 (en) 2013-01-29 2021-10-19 Otsuka Pharmaceutical Co., Ltd. Highly-swellable polymeric films and compositions comprising the same
WO2014144738A1 (en) 2013-03-15 2014-09-18 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
WO2014151929A1 (en) 2013-03-15 2014-09-25 Proteus Digital Health, Inc. Personal authentication apparatus system and method
JP6511439B2 (ja) 2013-06-04 2019-05-15 プロテウス デジタル ヘルス， インコーポレイテッド データ収集および転帰の査定のためのシステム、装置、および方法
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
RU2736776C2 (ru) 2013-09-20 2020-11-20 Протеус Диджитал Хелс, Инк. Способы, устройства и системы приема и декодирования сигналов в присутствии шума с использованием срезов и деформирования
JP2016537924A (ja) 2013-09-24 2016-12-01 プロテウス デジタル ヘルス， インコーポレイテッド 事前に正確に把握されていない周波数において受信された電磁信号に関する使用のための方法および装置
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
EP3487393A4 (en) 2016-07-22 2020-01-15 Proteus Digital Health, Inc. ELECTROMAGNETIC DETECTION AND DETECTION OF ENHANCED EVENT MARKERS
US10820831B2 (en) 2016-10-26 2020-11-03 Proteus Digital Health, Inc. Methods for manufacturing capsules with ingestible event markers
CN111214456A (zh) * 2020-03-10 2020-06-02 浙江普利药业有限公司 伏立康唑干混悬剂及其制备方法
PE20231844A1 (es) * 2020-07-30 2023-11-21 Faes Farma Sa Sistema de liberacion de farmacos descongestivos y bilastina
CN112198274B (zh) * 2020-11-02 2022-04-05 北京市理化分析测试中心 一种检测氨酚伪麻片中盐酸伪麻黄碱的方法
CN113514579A (zh) * 2021-06-23 2021-10-19 远大生命科学(武汉)有限公司 一种依托咪酯乳状注射液体外释放曲线的测定方法
CN115647000B (zh) * 2022-10-26 2025-06-27 华能阜新风力发电有限责任公司 一种基于低温热解的风电叶片回收方法及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4203439A (en) * 1976-11-22 1980-05-20 Alza Corporation Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
IE60383B1 (en) * 1988-05-27 1994-07-13 Elan Corp Plc Controlled release pharmaceutical formulation
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
ZA932272B (en) * 1992-03-30 1993-10-19 Alza Corp Viscous suspensions of controlled-release drug particles
US5718700A (en) * 1994-09-20 1998-02-17 Alza Corporation Exit means in dosage form
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
ES2203963T3 (es) * 1997-05-30 2004-04-16 Osmotica Corp. Dispositivo osmotico multicapa.
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system

Also Published As

Publication number Publication date
PL377479A1 (pl) 2006-02-06
CA2508722A1 (en) 2004-06-24
BR0317275A (pt) 2005-11-08
EP1572163A1 (en) 2005-09-14
RU2005118101A (ru) 2006-01-20
ZA200503812B (en) 2006-07-26
WO2004052343A1 (en) 2004-06-24
CO5570656A2 (es) 2005-10-31
MXPA05005812A (es) 2005-08-16
NO20053068L (no) 2005-09-07
AU2003283688A1 (en) 2004-06-30
KR20050088311A (ko) 2005-09-05
NZ539915A (en) 2007-09-28
JP2006510655A (ja) 2006-03-30
AR042340A1 (es) 2005-06-15
NO20053068D0 (no) 2005-06-22
TW200425888A (en) 2004-12-01
US20040121015A1 (en) 2004-06-24
RU2308263C2 (ru) 2007-10-20
CN1726012A (zh) 2006-01-25

Similar Documents

Publication Publication Date Title
TWI257302B (en) Controlled-release of an active substance into a high fat environment
Abrahamsson et al. Food effects on tablet disintegration
JP4100910B2 (ja) ヒドロゲル駆動の薬物剤形
Dehghan et al. Gastroretentive drug delivery systems: A patent perspective
BG107538A (bg) Дозирана лекарствена форма с хидрогелен механизъм
BR112015020453B1 (pt) Formas de dosagem de liberação prolongada orais de tofacitinibe e uso de tofacitinibe
DK1916995T3 (en) PH-CONTROLLED, PULSED delivery, METHODS OF MAKING AND USE THEREOF
KR20090014392A (ko) 결장 흡수용 페닐에프린 약제학적 제형 및 조성물
KR20080008352A (ko) 페노피브르산 및/또는 이의 염을 포함하는 경구 약제학적제형
JP2022104916A (ja) 自己調節性の浸透性胃保持性薬物送達システム
AU2013290875A1 (en) Gastro-retentive drug delivery system
WO2014154029A1 (zh) 复合骨架材料及其药物组合物
CN102639117A (zh) 1-[2-(2,4-二甲基-苯基硫基)-苯基]哌嗪的新组合物
US20150202158A1 (en) Gastro-retentive drug delivery system
Prajapati et al. Polymers for floating drug delivery system.
JP6454630B2 (ja) ｐＨ制御パルス送達システム、その調製法及び使用法
Rujivipat Novel formulation and processing aspects for compression coated tablets and for the compression of polymer-coated multiparticulates
NZ565272A (en) pH-controlled pulsatile delivery system, methods for preparation and use thereof
HK1083588A (en) Controlled-release of an active substance into a high fat environment
JP2017203031A (ja) ｐＨ制御パルス送達システム、その調製法及び使用法
Darunkaisorn Factors affecting the release of propranolol hydrochloride from hydroxypropyl methylcellulose matrix system filled in capsule as single-unit and multiple-unit
JP2014139210A (ja) ｐＨ制御パルス送達システム、その調製法及び使用法

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees